pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
EGFR · news · pharmadog
← back to EGFR
News · EGFR
138
stories
3d
ArriVent sheds nearly half of value on late-stage lung cancer miss
biospace
4d
ArriVent collapses on disappointing lung cancer data
biopharma dive
4d
ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks
endpoints
4d
ArriVent’s phase 3 lung cancer trial flops, sinking stock
fiercebiotech
5d
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
fiercebiotech
10d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
10d
No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins
biospace
11d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
18d
Compass vows to press on with FDA application despite new trial request
biospace
18d
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
23d
Rare EGFR mutation increases lung cancer risk 62 times in never smokers
fiercebiotech
25d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
25d
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
biospace
29d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 8, 26
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
Sep 8, 26
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
Sep 7, 26
BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
fiercebiotech
Sep 3, 26
GSK wagers up to $1.3B on a different kind of cancer drug
biopharma dive
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 3, 26
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
biospace
Sep 3, 26
GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront
endpoints
Sep 3, 26
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
fiercebiotech
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 19, 26
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 17, 26
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
Aug 17, 26
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
biospace
← prev
page 1 of 5
next →
